In more recent years, a pivotal article by Hoogstins CES et al., published in 2018, “Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infrared Fluorescent Agent,” marked a trend with an intensity of 5.18. The gene discussed is CEACAM5; the disease is familial pancreatic carcinoma.